摘要
目的研究分析在急性脑梗死疾病治疗过程中应用丁苯酞与依达拉奉联合用药的临床治疗疗效。方法选择2017年9月—2019年7月期间该院收治的128例急性脑梗死患者作为观察对象,根据所有观察对象接受治疗方式的不同分为观察组(接受丁苯酞与依达拉奉联合用药治疗方式)与对照组(接受单纯丁苯酞药物治疗方式),各64例。对比观察两组患者接受治疗后临床治疗疗效、日常生活活动能力量表与神经功能损伤程度评分情况、药物不良反应发生情况。结果观察组接受治疗后临床治疗疗效总有效率87.50%显著优于对照组73.44%(χ~2=4.026,P=0.045);观察组接受治疗后日常生活活动能力评分(59.87±6.73)分以及神经功能损伤程度(15.22±2.68)分评分情况均优于对照组(50.62±6.29)分、(19.23±2.97)分,差异有统计学意义(t=8.033、8.019,P<0.05);观察组患者药物不良反应发生率12.50%比对照组14.06%低,但差异无统计学意义(χ~2=0.068,P=0.794)。结论应用丁苯酞与依达拉奉联合用药治疗急性脑梗死疾病患者具有显著的临床疗效,对于患者神经功能以及日常活动能力具有明显的改善效果,并且不会增加药物不良反应发生情况。
Objective To study and analyze the clinical therapeutic effect of butylphthalide combined with edaravone in the treatment of acute cerebral infarction.Methods From September 2017 to July 2019,128 patients with acute cerebral infarction admitted to the hospital were selected as observation objects,and they were divided into observation group(receiving butylphthalide combined with edaravone medication)and the control group(received treatment with butylphthalide alone),64 cases in each group.After comparing the two groups of patients with clinical treatment efficacy,daily life activity scale and neurological impairment score,the occurrence of adverse drug reactions.Results The total effective rate of clinical treatment after treatment in the observation group was 87.50%,which was significantly better than that in the control group 73.44%(χ~2=4.026,P=0.045);the observation group’s daily life activity scale(59.87±6.73)points and nerve degree of functional impairment(15.22±2.68)points was better than that of the control group(50.62±6.29)points and(19.23±2.97)points,with significant differences(t=8.033,8.019,P<0.05);the observation group had poor medication reaction rate of 12.50%was lower than that of the control group of 14.06%,and there was no statistical difference(χ~2=0.068,P=0.794).Conclusion The combined use of butylphthalide and edaravone in the treatment of patients with acute cerebral infarction disease has a significant clinical effect,and it has a significant improvement effect on the patient’s nerve function and daily activity ability,and will not increase the incidence of adverse drug reactions.
作者
孙瑛
董美玲
王玉慧
周媛媛
SUN Ying;DONG Mei-ling;WANG Yu-hui;ZHOU Yuan-yuan(Department of Neurology,Qingdao Ninth People's Hospital,Qingdao,Shandong Province,266000 China)
出处
《系统医学》
2020年第13期19-21,共3页
Systems Medicine
关键词
丁苯酞
依达拉奉
急性脑梗死
疗效
Butylphthalide
Edaravone
Acute cerebral infarction
Efficacy